4 results
CAEB071A2206 will assess safety, efficacy and target trough levels for optimal dosing of AEB071 combined with Certican in a CNI-free regimen in de novo renal transplant recipients. This study will combine the investigational drug AEB071 with an…
The purpose of this extension is to provide continued treatment and to assess the long term safety, efficacy and tolerability of oral AEB071 plus Certican® vs. Neoral® plus Certican® in de novo renal transplant recipients. The study is a…
The purpose of this study is to determine the safety and efficacy of post-surgery treatment with the monoclonal antibody ipilimumab, to see whether treatment improves recurrence-free survival (RFS), overall survival and distant metastases-free…
The aim of this research is:1. To test the safety of MK-1308A, MK-4280A, MK-7684A and MK 4830 + pembrolizumab against pembrolizumab as the single agent.2. To test how well MK-1308A, MK-4280A, MK-7684A and MK-4830 + pembrolizumab are tolerated by…